Junevity, a biotechnology company dedicated to extending lifespan and enhancing healthspan by targeting cellular damage at its root, has announced a remarkable $10 million in seed funding led by Goldcrest Capital and Godfrey Capital. This significant investment marks a pivotal moment for the company, which is leveraging its breakthrough RESET platform—developed from exclusively licensed research by co-founder Dr. Janine Sengstack at the University of California at San Francisco—to harness large-scale human data and advanced artificial intelligence in identifying key transcription factors that regulate cell damage. By pinpointing these targets, Junevity is pioneering a new class of siRNA therapeutics designed to reset cellular transcription back to a healthy state, thereby addressing complex diseases such as Type 2 diabetes, obesity, frailty, and even neurodegeneration. The company’s innovative approach is underpinned by the creation of the Cell RESET Atlas, a comprehensive compilation of promising transcription factor targets categorized by cell type and disease, which lays the groundwork for personalized and targeted therapeutic interventions.
Preclinical studies have underscored the transformative potential of the RESET platform, with the company’s first siRNA candidate in a Type 2 diabetes model demonstrating improved glucose control and enhanced insulin sensitivity in diabetic mice without the adverse side effects typically seen with conventional treatments. In parallel, a second siRNA candidate targeting obesity has shown a striking ability to improve adipose tissue metabolism and reduce food intake, resulting in a 30% weight loss driven by fat reduction while preserving lean mass. This innovative therapeutic approach also offers the added benefit of infrequent dosing—ranging from once every three to twelve months—which promises to significantly enhance patient compliance and satisfaction. Such compelling data not only validate the scientific rationale behind the RESET platform but also highlight its potential to fundamentally alter the way metabolic and age-related diseases are managed by addressing the underlying transcriptional imbalances that contribute to cell aging.
The vision behind Junevity is further bolstered by a world-class team of industry leaders and innovators. Co-founder and CEO Dr. John Hoekman, whose previous achievements include developing the technology behind Impel Pharmaceuticals’ Trudhesa® nasal spray, is passionately steering the company toward advancing multiple clinical programs that could transform treatments for diseases of aging. Alongside him, co-founder and Chief Scientific Officer Dr. Janine Sengstack, whose groundbreaking research at UCSF revealed the potential of targeting transcription factors to restore cellular vitality, continues to drive forward the development of novel therapeutic candidates. Complementing this leadership is Rob Cahill, co-founder and COO, whose expertise in machine learning and previous entrepreneurial success adds a critical dimension to Junevity’s operational strategy. Supported by industry stalwarts like Brent Saunders, CEO and chairman of Bausch + Lomb, the company is poised to not only tackle the complex challenges of metabolic and age-related diseases but also to redefine the boundaries of human longevity and cellular health.